Impact of FLT3ITD mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia

Blood

Volumn 124, Issue 2, 2014, Pages 273-276

  Linch, David C ^a   Hills, Robert K ^b   Burnett, Alan K ^b   Khwaja, Asim ^a   Gale, Rosemary E ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLT3 LIGAND; NUCLEOPHOSMIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLELE; ARTICLE; CANCER INCIDENCE; CANCER RECURRENCE; CANCER RISK; HUMAN; LEUKEMIA CELL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ALLELES; FMS-LIKE TYROSINE KINASE 3; GENE DOSAGE; GENE DUPLICATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MINISATELLITE REPEATS; MUTATION; PROGNOSIS; RECURRENCE; RISK; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84904124365     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-02-554667     Document Type: Article

References (11)

1. Marcucci G, Haferlach T, Döhner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol. 2011;29(5):475-486.
2. Ofran Y, Rowe JM. Genetic profiling in acute myeloid leukaemia - where are we and what is its role in patient management. Br J Haematol. 2013;160(3):303-320.
3. O'Donnell MR, Abboud CN, Altman J, et al. Acute myeloid leukemia. J Natl Compr Canc Netw. 2012;10(8):984-1021.
4. Cornelissen JJ, Gratwohl A, Schlenk RF, et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol. 2012;9(10):579-590.
5. Whitman SP, Archer KJ, Feng L, et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res. 2001;61(19):7233-7239.
6. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99(12):4326- 4335.
7. Gale RE, Green C, Allen C, et al Medical Research Council Adult Leukaemia Working Party. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood. 2008;111(5):2776-2784.
8. Schnittger S, Bacher U, Kern W, Alpermann T, Haferlach C, Haferlach T. Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia. Leukemia. 2011;25(8):1297-1304.
9. Pratcorona M, Brunet S, Nomdedéu J, et al Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas Mieloblásticas. Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. Blood. 2013;121(14):2734-2738.
10. Schneider F, Hoster E, Unterhalt M, et al. The FLT3ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotype. Blood. 2012;119(19):4383-4386.
11. Grimwade D, Hills RK, Moorman AV, et al National Cancer Research Institute Adult Leukaemia Working Group. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354-365.